The University of Southampton
University of Southampton Institutional Repository

Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?

Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is known to be associated with significant insulin resistance and increased risk of cardiovascular disease. .Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been shown to inhibit Niemann-Pick C1-like 1 (NPC1L1) . Interestingly, NPC1L1 is abundantly expressed in human liver as well as in the intestine. Recent reports suggest a potential benefit of ezetimibe in improving hepatic insulin sensitivity and decreasing hepatic inflammation and lipid accumulation. The presence of insulin resistance and excess hepatic fat accumulation are regarded as key factors in the pathogenesis of NAFLD. Therefore, we suggest that urgent studies are needed to assess the potential therapeutic benefit of ezetimibe in treating NAFLD.
1359-6446
590-595
Ahmed, Mohamed H.
ed037a05-9770-4c1f-80a8-bd79fc83ee35
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Ahmed, Mohamed H.
ed037a05-9770-4c1f-80a8-bd79fc83ee35
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c

Ahmed, Mohamed H. and Byrne, Christopher D. (2010) Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discovery Today, 15 (15-16), 590-595. (doi:10.1016/j.drudis.2010.06.007). (PMID:20601094)

Record type: Article

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is known to be associated with significant insulin resistance and increased risk of cardiovascular disease. .Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been shown to inhibit Niemann-Pick C1-like 1 (NPC1L1) . Interestingly, NPC1L1 is abundantly expressed in human liver as well as in the intestine. Recent reports suggest a potential benefit of ezetimibe in improving hepatic insulin sensitivity and decreasing hepatic inflammation and lipid accumulation. The presence of insulin resistance and excess hepatic fat accumulation are regarded as key factors in the pathogenesis of NAFLD. Therefore, we suggest that urgent studies are needed to assess the potential therapeutic benefit of ezetimibe in treating NAFLD.

Text
Ezetimbe_-_Drug_Discovery_Today_-__May_2010.pdf - Author's Original
Restricted to Repository staff only
Request a copy

More information

Published date: August 2010

Identifiers

Local EPrints ID: 158221
URI: https://eprints.soton.ac.uk/id/eprint/158221
ISSN: 1359-6446
PURE UUID: 48b4930d-976c-44c6-a82b-e6078f6cd5d4
ORCID for Christopher D. Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 16 Jun 2010 13:38
Last modified: 20 Jul 2019 01:09

Export record

Altmetrics

Contributors

Author: Mohamed H. Ahmed

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×